Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.

J Immunother Cancer · 2024 · PMC11043783 · PMID 38658031

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

almost significantno p-value reported

A significant or almost significant change in the growth of non-injected B16-F10-OVA lesions and subsequent survival was observed in anti-CTLA-4+TT and anti-PD-1/CTLA-4+TT combinations only (at both 15 and 30 μg TT), when compared with either anti-CTLA-4+vehicle, anti-PD-1/CTLA-4+vehicle or IgG+TT-treated mice ( figure 7E, F ; online supplemental figure 13 ; “Non-injected” panels).

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.